Autosomal dominant spastic paraplegia type 8

Get in touch with RARE Concierge.

Contact RARE Concierge

Synonyms: SPG8

A rare pure or complex form of hereditary spastic paraplegia characterized by early adulthood onset of slowly progressive lower limb spasticity resulting in gait disturbances hyperreflexia and extensor plantar responses urinary urgency and/or incontinence muscle weakness decreased vibration sense and mild muscular atrophy in lower extremities. It may be associated with complicating signs such as sensory neuropathy ataxia (i.e. mild dysmetria uncoordinated eye movement) and mild dysphagia.

Data from Orphanet are used to provide information on a disease's name, synonym(s), and overview. Reference: Access aggregated data from Orphanet at Orphadata. Orphadata: Free access data from Orphanet. © INSERM 1999. Available on http://www.orphadata.org. Data version May 2024

Newly diagnosed with
Autosomal dominant spastic paraplegia type 8?

Our RARE Concierge Services Guides are available to assist you by providing information, resources and connections as you navigate your rare disease journey.

Get Concierge Help

Advocacy Organizations

Genetic Support Network of Victoria

The Genetic Support Network of Victoria is an organisation that supports people living with genetic, undiagnosed and rare conditions and those who support them including community and families, patient support organisations, health professionals and industry. Our vision is our community flourishing and living their best lives.

National Ataxia Foundation

Ataxia is a rare neurological disease affecting tens of thousands of people in the US and many thousands more around the world. It is progressive, affecting a person’s ability to walk, talk, and use fine motor skills. The National Ataxia Foundation (NAF) was established in 1957 to help persons with Ataxia and their families. Our mission is to accelerate the development of treatments and a cure

Don't see your organization here. Let us know here.

Clinical Trials

For a list of clinical trials in this disease area, please click here.